- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04102475
Efficacy of a Phone-based Relapse Prevention for Anorexia Nervosa After a First Hospitalization (EATLINE)
Anorexia Nervosa (AN) is a highly challenging disease which consequences are serious. Relapse rate is estimated between 38 and 41% during the year following hospitalization. The efficacy of patients' phone contact procedure on relapse has been assessed and has shown interest in numerous disorders. However, no study has ever used phone contact as a relapse prevention intervention tool in AN.
Objective: To evaluate efficacy of a phone contact procedure to increase body weight at 12 months after a first hospitalization for AN, by comparison to standard medical follow-up. Secondary objectives are to evaluate effect of phone contact procedure on: change in body weight at 6 month, general psychopathology disorder, psychopathology disorder specific to AN, rate of usual follow-up visit, and medico-economic impact.
Method: Prospective, multicenter, open-label, randomized controlled clinical trial, for subject over 15 years old presenting with diagnosis of AN. Patients randomized in EATLINE group will be contacted by phone at 15 days, 1, 2, 4 and 9 months after discharge from hospitalization. Patients in control group will benefit from usual follow-up.
Expected outcomes and perspectives:that there will be a significant decrease in relapse due to phone contact procedure compared to control group. Results would justify additional devices at the end of hospitalization, until development of various connected tools allowing to "stay in contact" with patients in order to optimize the current therapeutic possibilities of AN.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Hénin-Beaumont, France
- Centre Hospitalier Général
-
Lille, France
- Hôpital Fontan2, CHU
-
Lille, France
- Hôpital Saint Vincent de Paul, GHICL
-
Loos, France
- Cliniqie Lautreamont
-
Montpellier, France
- CHU de Montpellier
-
Nantes, France
- Centre Hospitalier Universitaire
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subject over 15 years of age
- Diagnosis of AN (restrictive and/or purgative) according to DSM-5 criteria
- Included after a first inpatient hospitalization in specialized care
- Providing informed, dated and signed consent (for a minor, consent must be signed by both parents who have parental authority )
- With medical insurance
- Can be reached by telephone
Exclusion Criteria:
- Uncompensated psychiatric pathology
- Refusal to participate in the study
- The inability to consent to care (patient or his/her legal representative)
- Pregnancy
- Major incapable subject or under guardianship or judicial protection
- Homelessness
- No mastery of reading and writing
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Sham Comparator: control group
|
After discharge from the first hospitalization:
|
|
Experimental: eatline group
|
After discharge from a first hospitalization: Phone calls at 15 days, 1, 2, 4 and 9 months by a trained psychologist. The phone interview will be guided by the same standardized frame, which was developed by a group of experts and tested with a group of patients. The purpose of this intervention is to provide a therapeutic and motivational approach, with positive reinforcement and reassurance.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
change in body mass index (BMI)
Time Frame: from discharge of the first hospitalization to 12 months.
|
from discharge of the first hospitalization to 12 months.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
change in BMI from the first hospitalization
Time Frame: from the first hospitalization to 6 months and at 1 year
|
from the first hospitalization to 6 months and at 1 year
|
|
Mini International Neuropsychiatric Interview (MINI)
Time Frame: at baseline, at 6 months , at 1 year
|
at baseline, at 6 months , at 1 year
|
|
SCID-2 (Structured Clinical Interview for DSM IV Axis II Personality Disorders)
Time Frame: at baseline, at 6 months , at 1 year
|
at baseline, at 6 months , at 1 year
|
|
The level of psychopathology specific to AN assessed by EDI (Eating Disorders Inventory)
Time Frame: at baseline, at 6 months , at 1 year
|
at baseline, at 6 months , at 1 year
|
|
The level of psychopathology specific to AN assessed BSQ (Body Shape Questionnaire)
Time Frame: at baseline, at 6 months , at 1 year
|
at baseline, at 6 months , at 1 year
|
|
The level of psychopathology specific to AN assessed by WCS (Weight and Shape Concern Scale)
Time Frame: at baseline, at 6 months , at 1 year
|
at baseline, at 6 months , at 1 year
|
|
Rate of patients lost to follow-up visits
Time Frame: during the one year
|
during the one year
|
|
Rate of patients with at least one re-hospitalization or earlier consultations than expected
Time Frame: during the one year
|
during the one year
|
|
Medico-economic evaluation with the MEDEC questionnaire
Time Frame: at 6 months, at 1 year
|
at 6 months, at 1 year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Olivier COTTENCIN, MD,PhD, University Hospital, Lille
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2017_73
- 2018-A02536-49 (Other Identifier: ID-RCB number, ANSM)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.